FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CHA	NGES IN	I BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hansen Shannon Marie</u>					2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC TNDM								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					vner		
(Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC 11075 ROSELLE STREET					02/	3. Date of Earliest Transaction (Month/Day/Year) 02/15/2022									SVP & General Counsel					
(Street)			92121		4.11							ine)	•				n			
(City)	(S1		(Zip)													-				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/E			action	ay/Year) Execution Date, if any (Month/Day/Year) Transac Code (Ir		ion	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		red (A) o str. 3, 4 a	5. Amount of Securities Beneficially Owned Followin Reported		nt of es ally Following d ion(s)	Form: Direct (D) or Indirect g (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)					
		Т							uired, Dis						owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year)		Date,		ransaction of E Code (Instr. Derivative (N		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Set (Instr. 3 and 4			f s g Securit	8. Price o Derivative Security (Instr. 5)			ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
					Code	v	(A)	(D)	Date Exercisable	Ex Da	piration te	Title	Amour or Number of Shares	ber						
Restricted Stock Unit ⁽¹⁾	(2)	02/15/2022			A		8,492		(3)		(3)	Common Stock	8,492	2	\$0	8,492		D		

Explanation of Responses:

- 1. Awarded on February 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
- 2. Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the Company.
- 3. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one-year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.

Remarks:

/s/ Shannon Hansen

02/17/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.